OncoMatch/Clinical Trials/NCT06612840
A Study of GNC-077 in Patients With Locally Advanced or Metastatic Non-small-cell Lung Cancer and Other Solid Tumors
Is NCT06612840 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies GNC-077 for non-small cell lung cancer.
Treatment: GNC-077 — This study is an open-label, multicenter, dose-escalation and cohort expansion phase I clinical study to evaluate the safety, tolerability, pharmacokinetics characteristics or preliminary efficacy and antitumor activity in patients with Locally advanced or metastatic non-small cell lung cancer and other solid tumors.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Tumor Agnostic
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: chemotherapy
Chemotherapy ... have been used within 4 weeks or 5 half-lives before the first dose
Cannot have received: biological therapy
biological therapy ... have been used within 4 weeks or 5 half-lives before the first dose
Cannot have received: immunotherapy
immunotherapy ... have been used within 4 weeks or 5 half-lives before the first dose
Cannot have received: mitomycin (mitomycin)
Mitomycin ... administered within 6 weeks before the first dose
Cannot have received: nitrosoureas (nitrosoureas)
nitrosoureas ... administered within 6 weeks before the first dose
Cannot have received: antimetabolite (fluorouracil)
Oral drugs such as fluorouracil
Lab requirements
Blood counts
bone marrow function should meet the requirements
Kidney function
renal function should meet the requirements
Liver function
liver function should meet the requirements
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify